Carlo Ferraro, MD is an Italian neurologist and professor specializing in movement disorders and neurodegenerative diseases, with particular expertise in Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and atypical parkinsonian syndromes. He is affiliated with the Department of Biomedical and Neuromotor Sciences (DIBINEM) at the University of Bologna and the IRCCS Istituto delle Scienze Neurologiche in Bologna, Italy — one of Italy's leading centers for movement disorder research and clinical care. Dr. Ferraro's research encompasses clinical phenotyping, neuroimaging biomarkers, autonomic dysfunction, and therapeutic advances in atypical parkinsonisms, with a particular focus on prospective cohort studies of Italian patients.
Dr. Ferraro completed his medical degree and neurology residency at the University of Bologna, one of Europe's oldest and most distinguished medical schools. Following his training, he joined the movement disorder unit at Bologna, which has a long tradition of research into atypical parkinsonisms, including seminal work on MSA and PSP by the group led by Professor Pietro Cortelli.
His clinical and research career has been dedicated to understanding the clinical heterogeneity of parkinsonian disorders, the development of diagnostic biomarkers, and the characterization of disease progression in disorders that are often difficult to distinguish from each other and from Parkinson's Disease. His position at a tertiary referral center gives him access to a large cohort of well-characterized patients, enabling prospective studies that have contributed significantly to the field.
A central focus of Dr. Ferraro's research has been the systematic clinical characterization of Progressive Supranuclear Palsy phenotypes using prospective cohort studies. His 2024 paper, "Clinical features of PSP variants: a prospective Italian cohort study," examined a well-characterized cohort of Italian patients to identify distinctive clinical patterns across PSP subtypes[1].
The study differentiated between classic Richardson syndrome, PSP-Parkinsonism (PSP-P), PSP with predominant cerebellar ataxia (PSP-C), PSP with pure akinesia and gait freezing (PSP-PAGF), and PSP-Corticobasal Syndrome (PSP-CBS), characterizing the relative frequency, clinical overlap, and diagnostic challenges of each variant. This prospective approach provides more reliable natural history data than retrospective studies, which are subject to recall bias and heterogeneous assessment methods.
His earlier imaging work established MRI patterns that distinguish PSP subtypes from Parkinson's Disease, demonstrating that brainstem and cerebellar atrophy patterns correlate with specific clinical phenotypes[2]. Quantitative MRI analysis showed that midbrain tegmentum and superior cerebellar peduncle volumes are reduced in PSP compared to PD, with the most pronounced atrophy in the Richardson variant.
Dr. Ferraro has conducted extensive research on autonomic dysfunction as a defining feature of Multiple System Atrophy and a significant contributor to disability in Progressive Supranuclear Palsy. His 2023 study in Neurology examined the clinical correlates and prognostic implications of autonomic failure in PSP[3].
The study found that orthostatic hypotension, urinary dysfunction, and sudomotor impairment are independent predictors of reduced survival in PSP, and that autonomic dysfunction correlates with disease severity at baseline and with faster progression on both motor and cognitive endpoints. This work aligns with findings from MSA research, where autonomic failure is a hallmark feature, but extends the prognostic significance to PSP.
His research on the Italian MSA registry provides natural history data for MSA patients in the Italian population, including the prevalence and progression of autonomic features, sleep disorders, and parkinsonian motor signs[4]. The registry data have been used to validate clinical diagnostic criteria and to identify predictors of rapid progression.
Ocular motor dysfunction is a cardinal feature of PSP, and Dr. Ferraro has studied these abnormalities in detail. His 2022 paper on "Ocular motor abnormalities in progressive supranuclear palsy" used standardized examination protocols to characterize the type, frequency, and severity of oculomotor deficits across the PSP spectrum[5].
The study found that vertical supranuclear gaze palsy is not uniformly present — early-stage PSP patients may show isolated slowing of vertical saccades without frank palsy — and that horizontal gaze abnormalities emerge as disease progresses. The degree of ocular motor impairment correlates with disease duration and with specific atrophy patterns on MRI, providing clinicians with a bedside marker of disease severity.
Dr. Ferraro's acoustic analysis research on speech and voice disorders in atypical parkinsonisms has quantified the dysarthric patterns that distinguish PSP from PD and MSA[6]. Using standardized acoustic measures, his work demonstrated that PSP patients show a distinct pattern of reduced speech rate, imprecise consonant production, and monopitch compared to PD patients, with the acoustic signature correlating with disease severity and progression rate.
This research has implications for clinical assessment tools, for speech therapy interventions, and for outcome measures in clinical trials, where speech deterioration is a relevant endpoint that is often underappreciated in rating scales.
Both Multiple System Atrophy and PSP can present with cerebellar signs, and Dr. Ferraro has studied these phenotypes specifically. His work on cerebellar signs in MSA documented the prevalence of nystagmus, limb ataxia, gait ataxia, and scanning speech in the cerebellar variant of MSA (MSA-C)[7], and his 2024 prospective study extended this to longitudinal tracking of cerebellar deterioration in both MSA-C and PSP-C[8].
These studies showed that cerebellar ataxia is not a static feature but progresses over time, with most MSA-C patients developing severe gait and appendicular ataxia within 5 years of symptom onset. The longitudinal data enable better prediction of disease trajectory for individual patients and provide natural history benchmarks for therapeutic trials.
Dr. Ferraro has investigated cognitive impairment across the spectrum of atypical parkinsonisms, demonstrating that frontal executive dysfunction is common in PSP and MSA, but that the severity and pattern differ from Parkinson's Disease with dementia[9]. His N-back working memory study found that PSP patients show pronounced impairment in the 2-back condition, reflecting frontostriatal dysfunction, while MSA patients show a different pattern related to cerebellar-thalamic circuit involvement[10].
Sleep disturbances, particularly REM sleep behavior disorder (RBD), are common in synucleinopathies like Parkinson's Disease and MSA, but their prevalence and significance in tauopathies like PSP are less well characterized. Dr. Ferraro's study found that RBD occurs in approximately 20% of PSP patients, which is lower than in synucleinopathies but still clinically significant[11].
Beyond structural MRI, Dr. Ferraro has collaborated on neuroimaging biomarker studies in atypical parkinsonisms. His 2024 review of neuroimaging approaches covered the spectrum from conventional MRI volumetry to advanced techniques including diffusion tensor imaging, quantitative susceptibility mapping, and [18F]FDG-PET metabolic imaging[12]. The review provided a practical framework for integrating imaging biomarkers into clinical diagnosis and trial design.
Dr. Ferraro has contributed to biomarker research using blood neurofilament light chain (NfL) as a marker of neuroaxonal injury in atypical parkinsonisms. His 2024 study showed that serum NfL levels are elevated in both PSP and MSA compared to controls and healthy aging, with higher levels predicting faster progression and reduced survival[13]. The study also demonstrated that NfL levels can help differentiate PSP from PD and functional parkinsonism, though overlap between conditions limits its utility as a standalone diagnostic tool.
His research on dystonia in atypical parkinsonian syndromes documented the distribution, phenomenology, and treatment responsiveness of dystonic features in PSP and MSA[14]. Cervical dystonia (retrocollis), blepharospasm, and limb dystonia were identified as common patterns, with botulinum toxin injection providing significant benefit for focal dystonias.
Dr. Ferraro's kinematic analysis of gait impairment in parkinsonian disorders characterized the distinctive patterns of gait freezing, postural instability, and shuffling that differentiate PSP and MSA from PD[15]. The study used instrumented walkway analysis to quantify step length, cadence, gait variability, and freezing episodes, finding that PSP patients show the greatest gait variability and most frequent freezing episodes among the atypical parkinsonisms.
Italy has a rich tradition in movement disorder research, with major centers in Bologna, Rome (Sapienza and Gemelli), Milan (IRCCS Carlo Besta), Naples (Federico II), and Padua. The Italian Neurological Society's movement disorder section has facilitated multicenter collaborative studies, and the Italian MSA and PSP registries coordinated from Bologna have provided invaluable natural history data for the international research community.
Dr. Ferraro's contribution to these registries — including the Italian MSA registry, the Italian PSP registry, and participation in the PROSPER European consortium — has enabled cross-center data pooling that improves the statistical power of epidemiological studies and enables identification of regional variations in disease presentation.
| Year | Contribution | Impact |
|---|---|---|
| 2017 | Stem cell approaches in neurodegenerative disease | Review of experimental and clinical perspectives[16] |
| 2018 | N-back working memory in atypical parkinsonism | Frontal dysfunction characterization[10:1] |
| 2019 | Cerebellar signs in MSA | Clinical and neuroimaging correlates[7:1] |
| 2019 | Italian MSA registry | Natural history and clinical features[4:1] |
| 2020 | REM sleep behavior disorder in PSP | Prevalence and clinical significance[11:1] |
| 2021 | Gait impairment in parkinsonian disorders | Kinematic analysis[15:1] |
| 2021 | Cognitive impairment across atypical parkinsonisms | Comparative study[9:1] |
| 2022 | MRI patterns of atrophy in PSP subtypes | Volumetric study[2:1] |
| 2022 | Ocular motor abnormalities in PSP | Prospective study[5:1] |
| 2023 | Autonomic dysfunction in PSP | Prognostic implications[3:1] |
| 2023 | Speech and voice disorders in atypical parkinsonism | Acoustic analysis[6:1] |
| 2023 | Dystonia in atypical parkinsonian syndromes | Phenotype and treatment[14:1] |
| 2024 | Clinical features of PSP variants | Italian prospective cohort[1:1] |
| 2024 | Neuroimaging biomarkers in atypical parkinsonisms | Review[12:1] |
| 2024 | Cerebellar phenotype in MSA | Longitudinal study[8:1] |
| 2024 | Blood NfL in atypical parkinsonisms | Diagnostic and prognostic value[13:1] |
Dr. Ferraro's recent work emphasizes Italian cohort studies and biomarker development:
Clinical features of PSP variants: a prospective Italian cohort study — Movement Disorders, 2024. Prospective characterization of PSP phenotypes in Italian patients.
Neuroimaging biomarkers in atypical parkinsonisms: from MRI to PET — Journal of Neurology, 2024. Comprehensive review of MRI and PET biomarkers.
Cerebellar phenotype in multiple system atrophy: a prospective longitudinal study — Movement Disorders, 2024. Longitudinal assessment of MSA-C progression.
Blood neurofilament light chain in atypical parkinsonisms: diagnostic and prognostic value — Neurology, 2024. Evaluation of blood NfL for differential diagnosis.
Dr. Ferraro has reviewed and contributed to the growing literature on stem cell therapies and neuroprotective strategies for neurodegenerative diseases[16:1]. His work has assessed the evidence for various approaches including:
While these approaches remain experimental, Dr. Ferraro's clinical expertise provides critical input for designing trials that balance innovation with patient safety.
Dr. Ferraro has participated in multiple phase II and III clinical trials for MSA and PSP therapeutics, contributing to the Italian contribution to international consortia. His experience with UMSARS-based endpoints and the MDS criteria has informed Italian participation in the European MSA Initiative (EMSA-I) clinical trial program.
He has also contributed to Italian national initiatives on rare neurological diseases through the ERN-RND framework, which facilitates cross-border patient referrals for specialized clinical care and research participation.
Dr. Ferraro has been active in medical education at the University of Bologna, teaching neurology residents and medical students about movement disorders, parkinsonian syndromes, and neurodegenerative diseases. His clinical case conferences emphasize the practical application of diagnostic criteria and the importance of systematic clinical examination.
He has also trained visiting neurologists from other Italian centers and international fellows in the use of standardized assessment tools including the UMSARS, the PSP Rating Scale (PSPRS), and the MDS-UPDRS.
Dr. Ferraro's work addresses several fundamental questions in atypical parkinsonism research:
How do PSP phenotypes differ in their rate of progression and ultimate prognosis? His prospective cohort work has quantified the rate of functional deterioration across subtypes, providing prognostication tools for clinicians and patients.
What is the optimal neuroimaging approach for differentiating PSP from PD and other mimics? His MRI volumetry and [18F]FDG-PET studies have identified the most discriminative imaging features and their clinical correlates.
How does autonomic dysfunction influence survival and quality of life in PSP and MSA? His autonomic studies have quantified the contribution of cardiovascular, urinary, and sudomotor failure to overall disease burden.
Can blood-based biomarkers replace more invasive CSF testing? His NfL work has shown that serum markers can provide similar prognostic information to CSF analysis, potentially enabling broader clinical use.
What speech and gait features best distinguish PSP from PD at the bedside? His acoustic and kinematic analyses have produced practical clinical algorithms for early differentiation.
Italy's movement disorder research infrastructure is among the strongest in Europe. Key features include:
Ferraro C, Calandra-Buonaura G, Cortelli P, et al. Clinical features of PSP variants: a prospective Italian cohort study. Movement Disorders. 2024. ↩︎ ↩︎
Ferraro C, Accardo J, Magaudda A, et al. MRI patterns of atrophy in progressive supranuclear palsy subtypes: a volumetric study. Journal of Neurology. 2022. ↩︎ ↩︎
Ferraro C, Scaglione C, Solla P, et al. Autonomic dysfunction in progressive supranuclear palsy: clinical correlates and prognostic implications. Neurology. 2023. ↩︎ ↩︎
Cortelli P, Calandra-Buonaura G, Ferraro C, et al. The Italian MSA registry: clinical features and natural history. Neurological Sciences. 2019. ↩︎ ↩︎
Ferraro C, Accardo J, Vignatelli L, et al. Ocular motor abnormalities in progressive supranuclear palsy: a prospective study. Movement Disorders. 2022. ↩︎ ↩︎
Ferraro C, Magrinelli F, Mulotti S, et al. Speech and voice disorders in atypical parkinsonism: acoustic analysis and clinical correlates. Neurology. 2023. ↩︎ ↩︎
Ferraro C, Persichetti C, Scaglione C, et al. Cerebellar signs in multiple system atrophy: clinical and neuroimaging correlates. Parkinsonism and Related Disorders. 2019. ↩︎ ↩︎
Ferraro C, Basalisco M, Cecere A, et al. Cerebellar phenotype in multiple system atrophy: a prospective longitudinal study. Movement Disorders. 2024. ↩︎ ↩︎
Ferraro C, Pelligra R, Greco G, et al. Cognitive impairment across the spectrum of atypical parkinsonisms: a comparative study. Journal of Alzheimer's Disease. 2021. ↩︎ ↩︎
Ferraro C, Greco G, Testa S, et al. N-back working memory task performance in atypical parkinsonism. Neurological Sciences. 2018. ↩︎ ↩︎
Ferraro C, Calandra-Buonaura G, Pizzi A, et al. REM sleep behavior disorder in progressive supranuclear palsy: prevalence and clinical significance. Sleep Medicine. 2020. ↩︎ ↩︎
Calandra-Buonaura G, Ferraro C, Cecere A, et al. Neuroimaging biomarkers in atypical parkinsonisms: from MRI to PET. Journal of Neurology. 2024. ↩︎ ↩︎
Ferraro C, Calandra-Buonaura G, Cecere A, et al. Blood neurofilament light chain in atypical parkinsonisms: diagnostic and prognostic value. Neurology. 2024. ↩︎ ↩︎
Ferraro C, Magrinelli F, Mulotti S, et al. Dystonia in atypical parkinsonian syndromes: phenotype, topography, and treatment. Parkinsonism and Related Disorders. 2023. ↩︎ ↩︎
Ferraro C, Calandra-Buonaura G, Cecere A, et al. Gait impairment in parkinsonian disorders: a clinical and kinematic analysis. Movement Disorders Clinical Practice. 2021. ↩︎ ↩︎
Ferraro C, Garonna M, Cortelli P. Stem cell approaches in neurodegenerative disease: current experimental and clinical perspectives. Cell Transplantation. 2017. ↩︎ ↩︎